Yamauchi Takuji 山内拓司

Researcher Number	20796213
Affiliation (Current)	2025: 九州大学, 大学病院, 助教
Affiliation (based on the past Project Information) *help	2018 – 2024: 九州大学, 大学病院, 助教 2017: 九州大学, 医学研究院, 特別研究員(PD)
Review Section/Research Field	Principal Investigator Basic Section 54010:Hematology and medical oncology-related Except Principal Investigator Medium-sized Section 54:Internal medicine of the bio-information integration and related fields / Broad Section I / Hematology
Keywords	Principal Investigator 急性骨髄性白血病 / AML / BCL2阻害 / Venetoclax / 分化誘導療法 / synthetic lethal / ATRA / MORC3 / HUSH / CRISPR / novel therapy … More Except Principal Investigator … More CRISPR/Cas9 / 急性骨髄性白血病 / 急性リンパ性白血病 / AML / CRISPR / 白血病 / 白血病幹細胞 / 機能的ジェノミックス / PROTAC / 機能ジェノミクス / BCL2阻害剤 / CRSPR/Cas9 / BCL2 / ALL / 合成致死 / p53 / TP53 / 急性白血病 / ゲノム編集 / プレmRNAプロセッシング / 分化誘導療法 / CRISPR/Cas9スクリーニング / PAICS / DCPS Less

Elucidation of ribosome biogenesis in leukemic stem cells and the establishment of a novel therapeutic application
- Principal Investigator
  
  赤司浩一
- Project Period (FY)
  2024 – 2026
- Research Category
  
  Grant-in-Aid for Scientific Research (A)
- Review Section
  
  Medium-sized Section 54:Internal medicine of the bio-information integration and related fields
- Research Institution
  Kyushu University
Development of novel therapy for AML using BCL2 inhibitorPrincipal Investigator
- Principal Investigator
  
  山内拓司
- Project Period (FY)
  2023 – 2025
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 54010:Hematology and medical oncology-related
- Research Institution
  Kyushu University
Development of novel therapeutic strategies for therapy-refractory leukemia
- Principal Investigator
  
  前田高宏
- Project Period (FY)
  2020 – 2024
- Research Category
  
  Grant-in-Aid for Scientific Research (S)
- Review Section
  
  Broad Section I
- Research Institution
  Kyushu University
Identifying molecular mechanisms underlying treatment-refractory leukemia and their targeting strategies
- Principal Investigator
  
  前田高宏
- Project Period (FY)
  2020
- Research Category
  
  Grant-in-Aid for Scientific Research (A)
- Review Section
  
  Medium-sized Section 54:Internal medicine of the bio-information integration and related fields
- Research Institution
  Kyushu University
Development of a new therapy for AML via CRISPR screenPrincipal Investigator
- Principal Investigator
  
  Yamauchi Takuji
- Project Period (FY)
  2019 – 2021
- Research Category
  
  Grant-in-Aid for Early-Career Scientists
- Review Section
  
  Basic Section 54010:Hematology and medical oncology-related
- Research Institution
  Kyushu University
急性骨髄性白血病に対するCRISPR全ゲノム機能的スクリーニング・新規治療法開発Principal Investigator
- Principal Investigator
  
  山内拓司
- Project Period (FY)
  2018 – 2021
- Research Category
  
  Grant-in-Aid for Early-Career Scientists
- Review Section
  
  Basic Section 54010:Hematology and medical oncology-related
- Research Institution
  Kyushu University
Identification of novel targets for leukemia therapy using genome-wide CRISPR/Cas9 screens
- Principal Investigator
  
  Takahiro Maeda
- Project Period (FY)
  2017 – 2019
- Research Category
  
  Grant-in-Aid for Scientific Research (A)
- Research Field
  
  Hematology
- Research Institution
  Kyushu University

All 2023 2020 2019 2018 2017

All Journal Article Presentation Patent

[Journal Article] Targeting a mitochondrial E3 ubiquitin ligase complex to overcome AML cell-intrinsic Venetoclax resistance2023
- Author(s)
  Nakao Fumihiko、Setoguchi Kiyoko、Semba Yuichiro、Yamauchi Takuji、Nogami Jumpei、Sasaki Kensuke、Imanaga Hiroshi、Terasaki Tatsuya、Miyazaki Manaka、Hirabayashi Shigeki、Miyawaki Kohta、Kikushige Yoshikane、Masuda Takeshi、Akashi Koichi、Maeda Takahiro
- Journal Title
  
  Leukemia
  
  Volume: - Issue: 5 Pages: 1028-1038
- DOI
  10.1038/s41375-023-01879-z
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-22K16323, KAKENHI-PROJECT-23K24364, KAKENHI-PROJECT-23K07816, KAKENHI-PROJECT-20H05699, KAKENHI-PROJECT-21H04827
[Journal Article] Establishment of a human SIRPA knock-in xenograft mouse model to study human hematopoietic and cancer stem cells2020
- Author(s)
  Jinnouchi Fumiaki、Yamauchi Takuji、Yurino Ayano、Nunomura Takuya、Nakano Michitaka、Iwamoto Chika、Obara Teppei、Miyawaki Kohta、Kikushige Yoshikane、Kato Koji、Maeda Takahiro、Miyamoto Toshihiro、Baba Eishi、Akashi Koichi、Takenaka Katsuto
- Journal Title
  
  Blood
  
  Volume: - Issue: 19 Pages: 1661-1672
- DOI
  10.1182/blood.2019002194
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-18K16366, KAKENHI-PROJECT-16H06391, KAKENHI-PROJECT-16H05340, KAKENHI-PROJECT-18H02840, KAKENHI-PROJECT-19H03687, KAKENHI-PROJECT-18K19565, KAKENHI-PROJECT-19K08818, KAKENHI-PROJECT-18K08362, KAKENHI-PROJECT-20H05699
[Journal Article] Genome-wide CRISPR-Cas9 Screen Identifies Leukemia-Specific Dependence on a Pre-mRNA Metabolic Pathway Regulated by DCPS.2018
- Author(s)
  Yamauchi T, et al.
- Journal Title
  
  Cancer Cell.
  
  Volume: 33 Issue: 3 Pages: 386-400
- DOI
  10.1016/j.ccell.2018.01.012
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-16H06391, KAKENHI-PROJECT-17H01567, KAKENHI-PROJECT-17H04208, KAKENHI-PROJECT-15J10130, KAKENHI-PROJECT-17K15042
[Journal Article] Molecular pathogenesis of disease progression in MLL-rearranged AML.2018
- Author(s)
  Kotani S, Yoda A, Kon A, Kataoka K, Ochi Y, Shiozawa Y, Hirsch C, Takeda J, Ueno H, Yoshizato T, Yoshida K, Nakagawa MM, Nannya Y, Kakiuchi N, Yamauchi T, Aoki K, Shiraishi Y, Miyano S, Maeda T, Maciejewski JP, Takaori-Kondo A, Ogawa S, Makishima H.
- Journal Title
  
  Leukemia
  
  Volume: 33 Issue: 3 Pages: 612-624
- DOI
  10.1038/s41375-018-0253-3
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-18K16084, KAKENHI-PLANNED-15H05909, KAKENHI-PROJECT-26221308, KAKENHI-PROJECT-17H01567, KAKENHI-PROJECT-16H05338, KAKENHI-PROJECT-17H04990, KAKENHI-PROJECT-17J05245, KAKENHI-PROJECT-17K19595, KAKENHI-PROJECT-19H01053
[Patent] Identification of 131 Acute Myeloid Leukemia (AML) essential genes2018
- Inventor(s)
  Maeda T, Yamauchi T, MaedaM
- Industrial Property Rights Holder
  Maeda T, Yamauchi T, MaedaM
- Industrial Property Rights Type
  特許
- Filing Date
  2018
- Acquisition Date
  2018
- Overseas
- Data Source
  KAKENHI-PROJECT-17H01567
[Patent] DCPS as a target for Acute Myeloid Leukemia2017
- Inventor(s)
  Maeda T, Yamauchi T, MaedaM
- Industrial Property Rights Holder
  Maeda T, Yamauchi T, MaedaM
- Industrial Property Rights Type
  特許
- Filing Date
  2017
- Acquisition Date
  2017
- Overseas
- Data Source
  KAKENHI-PROJECT-17H01567
[Presentation] PAICS, a de novo purine synthetic enzyme, is a novel target for AML therapy.2019
- Author(s)
  Yamauchi T, Miyawaki K, Semba Y, Nakao F, Nogami J, Sugio T, Sasaki K, Canver MC, Osborne S, Pinello L, Taylor D, Bauer DR, Akashi K, Maeda T.
- Organizer
  61th American Society of Hematology annual meeting
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17H01567
[Presentation] Genome-wide CRISPR screen identifies PAICS, and enzyme involved in de novo purine synthesis, as a potential target for AML therapy.2019
- Author(s)
  Yamauchi T, Miyawaki K, Semba Y, Nakao F, Nogami J, Sugio T, Sasaki K, Canver MC, Osborne S, Pinello L, Taylor D, Bauer DR, Akashi K, Maeda T
- Organizer
  FASEB: The Hematologic Malignancies Conference
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17H01567
[Presentation] PAICS inhibition is a potential therapeutic strategy for MYC-positive DLBCL2019
- Author(s)
  Miyawaki K, Yamauchi T, SugioT, Sasaki K, Miyoshi H, Osborne S, Taylor D, Ohshima K, Kato K, Maeda T, Akashi K
- Organizer
  61th American Society of Hematology annual meeting
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17H01567
[Presentation] CRISPR-Cas9 screen identifies Me2, a mitochondrial malic enzyme, as a molecule relevant for MCL1 inhibitor resistance in AML.2019
- Author(s)
  Nakao F, Yamauchi T, SembaY, Nogami J, Akashi K and Maeda T.
- Organizer
  61th American Society of Hematology annual meeting
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17H01567
[Presentation] CRISPR-Cas9 screen identifies XPO7 as a novel therapeutic target for TP53-mutated AML2019
- Author(s)
  SembaY, Yamauchi T, Nakao F, Nogami J, Canver MC, Pinello L, Bauer DE, Akashi K, Maeda T.
- Organizer
  Society of Hematologic Oncology (SOHO) 2019
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17H01567
[Presentation] CRISPR-Cas9 screen identifies Me2, a mitochondrial malic enzyme, as a molecule relevant for MCL1 inhibitor resistance2019
- Author(s)
  Nakao F, Yamauchi T, SembaY, Nogami J, Akashi K and Maeda T.
- Organizer
  FASEB: The Hematologic Malignancies Conference
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17H01567
[Presentation] PAICS inhibition is a potential therapeutic strategy for MYC-positive aggressive DLBCL2019
- Author(s)
  Miyawaki K, Yamauchi T, SugioT, Sasaki K, Miyoshi H, Osborne S, Taylor D, Ohshima K, Kato K, Maeda T, Akashi K
- Organizer
  Society of Hematologic Oncology (SOHO) 2019
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17H01567
[Presentation] CRISPR-Cas9 screen identifies XPO7 as a potential therapeutic target for TP53-mutated AML.2019
- Author(s)
  42.SembaY, Yamauchi T, Nakao F, Nogami J, Canver MC, Pinello L, Bauer DE, Akashi K, Maeda T.
- Organizer
  61th American Society of Hematology annual meeting
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17H01567
[Presentation] CRISPR-Cas9 screen identifies XPO7 as a novel therapeutic target for TP53-mutated AML2019
- Author(s)
  34.SembaY, Yamauchi T, Nakao F, Nogami J, Canver MC, Pinello L, Bauer DE, Akashi K, Maeda T.
- Organizer
  FASEB: The Hematologic Malignancies Conference
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17H01567
[Presentation] Targeting nuclear RNA metabolic pathways for the treatment of acute myeloid leukemia2017
- Author(s)
  Takuji Yamauchi
- Organizer
  日本血液学会
- Data Source
  KAKENHI-PROJECT-17H01567
[Presentation] Genome-wide CRISPR/Cas9 screen reveals that the DCPS scavenger decapping enzyme is essential for AML cell survival2017
- Author(s)
  Takuji Yamauchi
- Organizer
  American Society of Hematology
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17H01567

1. Takahiro Maeda (00791972)

# of Collaborated Projects: 3 results

# of Collaborated Products: 9 results
2. 菊繁吉謙 (40619706)

# of Collaborated Projects: 2 results

# of Collaborated Products: 0 results
3. 野上順平 (60801751)

# of Collaborated Projects: 2 results

# of Collaborated Products: 0 results
4. 増田豪 (70383940)

# of Collaborated Projects: 2 results

# of Collaborated Products: 0 results
5. 仙波雄一郎 (90816787)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
6. 赤司浩一 (80380385)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
7. 加藤光次 (20571764)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
8. 森康雄 (90573345)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
9. 昆彩奈

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
10. 平林茂樹

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
11. 岩本千佳

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results

Yamauchi Takuji 山内 拓司

Research Projects

Research Products

Co-Researchers

Elucidation of ribosome biogenesis in leukemic stem cells and the establishment of a novel therapeutic application

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Development of novel therapy for AML using BCL2 inhibitorPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Development of novel therapeutic strategies for therapy-refractory leukemia

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Identifying molecular mechanisms underlying treatment-refractory leukemia and their targeting strategies

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Development of a new therapy for AML via CRISPR screenPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

急性骨髄性白血病に対するCRISPR全ゲノム機能的スクリーニング・新規治療法開発Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Identification of novel targets for leukemia therapy using genome-wide CRISPR/Cas9 screens

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

[Journal Article] Targeting a mitochondrial E3 ubiquitin ligase complex to overcome AML cell-intrinsic Venetoclax resistance2023

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Establishment of a human SIRPA knock-in xenograft mouse model to study human hematopoietic and cancer stem cells2020

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Genome-wide CRISPR-Cas9 Screen Identifies Leukemia-Specific Dependence on a Pre-mRNA Metabolic Pathway Regulated by DCPS.2018

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Molecular pathogenesis of disease progression in MLL-rearranged AML.2018

Author(s)

Journal Title

DOI

Data Source

[Patent] Identification of 131 Acute Myeloid Leukemia (AML) essential genes2018

Inventor(s)

Industrial Property Rights Holder

Industrial Property Rights Type

Filing Date

Acquisition Date

Data Source

[Patent] DCPS as a target for Acute Myeloid Leukemia2017

Inventor(s)

Industrial Property Rights Holder

Industrial Property Rights Type

Filing Date

Acquisition Date

Data Source

Yamauchi Takuji 山内拓司